SCHEMBL5784

SCHEMBL5784

Cc1c(Cl)cccc1NC1=NCCC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.71
ADRA2B P18089 1/20 0.71
ADRA2C P18825 1/20 0.71
NISCH Q9Y2I1 1/20 0.57
KMT2A Q03164 3/20 0.50
POLB P06746 2/20 0.49
RAPGEF4 Q8WZA2 1/20 0.46
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
MT-CO2 P00403 1/20 0.43
LMNA P02545 1/20 0.43
TTR P02766 1/20 0.43
PLA2G1B P04054 1/20 0.43
CYP1A2 P05177 1/20 0.43
PGR P06401 1/20 0.43
CYP3A4 P08684 1/20 0.43
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6056 0.84 POLB (0.59) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL5534 0.83 ADRA2A (1.00) ADRA2AADRA2BADRA2CNISCHKMT2A
SCHEMBL5477 0.81 ADRA2A (0.71) ADRA2AADRA2BADRA2CNISCHKMT2A
SCHEMBL6690739 0.81 ADRA2A (0.54) ADRA2AADRA2BADRA2CNISCHKMT2A
SCHEMBL6475 0.81 ADRA2A (0.62) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL5896 0.81 ADRA2A (0.54) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL10857050 0.81 ADRA2A (0.54) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL5565 0.81 ADRA2A (0.54) ADRA2AADRA2BADRA2CKMT2APOLB
SCHEMBL6526 0.81 ADRA2A (0.66) ADRA2AADRA2BADRA2CNISCHKMT2A
Hydrochloric Acid SCHEMBL6892538 0.80 ADRA2A (0.53) ADRA2AADRA2BADRA2CNISCHKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491017-B1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN INC (US) 2014-08-27 EP claimed
US-20120238615-A1 Alpha adrenergic receptor modulators ALLERGAN, INC. (US) 2012-09-20 US claimed
CN-102666484-A Adrenergic receptor modulators ALLERGAN INC 2012-09-12 CN claimed
EP-2491017-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS Allergan, Inc. (US) 2012-08-29 EP claimed
WO-2011050030-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN, INC. (US) 2011-04-28 WO claimed
EP-2491017-B1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN INC (US) 2014-08-27 EP disclosed
US-20120238615-A1 Alpha adrenergic receptor modulators ALLERGAN, INC. (US) 2012-09-20 US disclosed
CN-102666484-A Adrenergic receptor modulators ALLERGAN INC 2012-09-12 CN disclosed
EP-2491017-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS Allergan, Inc. (US) 2012-08-29 EP disclosed
WO-2011050030-A1 ALPHA ADRENERGIC RECEPTOR MODULATORS ALLERGAN, INC. (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238615-A1 Alpha adrenergic receptor modulators ADRA2C, ADRB2, ADRB1 ADRA2A 4/4885ADRA2B 6/4885ADRA2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.